News
ABVC
0.8999
-6.20%
-0.0595
ABVC BioPharma Postpones Biokey (Cayman) Share Distribution, Rescheduled For August 21, 2026
Benzinga · 3d ago
Weekly Report: what happened at ABVC last week (0803-0807)?
Weekly Report · 5d ago
ABVC BioPharma Delays Planned BioKey Share Distribution
TipRanks · 08/04 10:33
ABVC Biopharma Inc trading halted, news pending
TipRanks · 08/03 20:45
Weekly Report: what happened at ABVC last week (0727-0731)?
Weekly Report · 08/03 09:21
Weekly Report: what happened at ABVC last week (0720-0724)?
Weekly Report · 07/27 09:22
Weekly Report: what happened at ABVC last week (0713-0717)?
Weekly Report · 07/20 09:21
Weekly Report: what happened at ABVC last week (0706-0710)?
Weekly Report · 07/13 09:21
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 07/09 17:05
Weekly Report: what happened at ABVC last week (0629-0703)?
Weekly Report · 07/06 09:22
Weekly Report: what happened at ABVC last week (0622-0626)?
Weekly Report · 06/29 09:21
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 06/22 12:05
Weekly Report: what happened at ABVC last week (0615-0619)?
Weekly Report · 06/22 09:24
Weekly Report: what happened at ABVC last week (0608-0612)?
Weekly Report · 06/15 09:24
Weekly Report: what happened at ABVC last week (0601-0605)?
Weekly Report · 06/08 09:22
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 06/04 12:05
Weekly Report: what happened at ABVC last week (0525-0529)?
Weekly Report · 06/01 09:24
Weekly Report: what happened at ABVC last week (0518-0522)?
Weekly Report · 05/25 09:25
ABVC BioPharma Q1 EPS $(0.06), Same YoY
Benzinga · 05/18 13:26
Weekly Report: what happened at ABVC last week (0511-0515)?
Weekly Report · 05/18 09:25
More
Webull provides a variety of real-time ABVC stock news. You can receive the latest news about Abvc Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About ABVC
ABVC Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The Company is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. It has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer.